StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
CRL 'Most Logical Outcome' for Sarepta's (SRPT) Eteplirsen - Janney Montgomery Scott
April 21, 2016 9:29 AM
Janney Montgomery Scott Weighed in on Sarepta Therapeutics (NASDAQ: SRPT) following today's FDA briefing documents, saying the writing is now ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
FDA
Short Sales
Trader Talk
Next Articles
Sarepta Therapeutics (SRPT) Sees Strong Mid-Day Upside
April 22, 2016 12:03 PM
RBC Sees Odds on Sarepta (SRPT) 9:1 Against
April 22, 2016 9:27 AM
Wedbush Downgrades Sarepta Therapeutic (SRPT) to Neutral (Yesterday)
April 22, 2016 7:24 AM
Buy Sarepta Therapeutic (SRPT) on Sell-Off - Needham & Company
April 22, 2016 6:40 AM
Sarepta (SRPT) PT Lowered to $23 at Baird as FDA Digs in for a Fight on Eteplirsen
April 21, 2016 4:53 PM
Oppenheimer Maintains Bullish View on Sarepta (SRPT) Despite Sell-Off on FDA Briefing Documents
April 21, 2016 1:20 PM
FDA Not Changing Etep Stance (SRPT) (BMRN) - Leerink
April 21, 2016 11:22 AM
Sarepta Therapeutics (SRPT) Sees Quick Sell-Off Following FDA Briefing Docs
April 21, 2016 8:08 AM
Sarepta Therapeutics (SRPT) on watch as FDA briefing documents hit
April 21, 2016 8:00 AM
Janney Capital Starts Sarepta Therapeutic (SRPT) at Neutral
April 20, 2016 8:03 AM
